Crisis Response Plan, Overdose Accidental, Overdose Antidote, Suicide
Conditions
Keywords
suicide, overdose, 988, naloxone
Brief summary
This pilot study evaluates the acceptability, appropriateness, and feasibility of a new crisis response training called Crisis Ready.
Detailed description
The study team conducted formative work to develop a new crisis response training for people involved in a law-enforcement assisted diversion program. The training, called Crisis Ready, combines an intervention that aims to promote use of 988 with a training on the use of Naloxone to reverse and overdose. The pilot aims to collect quantitative and qualitative data about the perceptions of the training among program participants and program staff.
Interventions
BEHAVIORALCrisis Ready Training
Crisis Ready Training combines Crisis Line Facilitation with Take Home Naloxone training. The intervention is delivered in a group format.
Sponsors
RAND
Henry Ford Health + Michigan State University Health Sciences
Brown University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participates in the Baltimore Crisis Response, Inc Law Enforcement Assisted Diversion Program * Capacity to give informed consent
Exclusion criteria
* Unable to understand English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability of Intervention Measure | Post-intervention (approximately 90 minutes on one day) | Participants' perspectives of the likability of the intervention. Scores range from 4 to 20, with higher scores indicating higher levels of acceptability. |
| Intervention Appropriateness Measure | Post-intervention (approximately 90 minutes on one day) | Measures the fit of the intervention for the population. Scores range from 4 to 20 with higher scores indicating higher levels of appropriateness. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perceptions of the Crisis Ready Training | Post-intervention (approximately 90 minutes on one day) | Participants rating of the quality of Crisis Ready and willingness to recommend the intervention to others |
| Attitudes About 988 | Post-intervention (approximately 90 minutes on one day) | Two-item assessments of comfort using 988 for oneself or others during a crisis. Responses are gathered from a Likert-type scale that ranges from 0 (not comfortable at all) to 10 (totally comfortable). Higher scores indicate higher levels of comfort using 988 for self or others. |
| Perception of 988 | Post-intervention (approximately 90 minutes on one day) | Perceptions of 988 utilization and couneslors |
| Knowledge of Naloxone | Post-intervention (approximately 90 minutes on one day) | Author created measure of knowledge about how to administer naloxone and where to obtain naloxone. |
| Attitudes About Naloxone | Pre- and Post-intervention (approximately 90 minutes on one day) | Four-item, author developed measures about comfort carrying and using naloxone in different circumstances. Responses are gathered from a Likert-type scale that ranges from 0 (not comfortable at all) to 10 (totally comfortable). Higher scores indicate higher levels of comfort carrying and using naloxone in different circumstances. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAlison J Athey, PhD
RAND
PRINCIPAL_INVESTIGATORSapna Mendon-Plasek, PhD
RAND
Participant flow
Recruitment details
Participants were recruited from the Baltimore Crisis Response, Inc Law Enforcement Assisted Diversion Program.
Baseline characteristics
| Characteristic | — |
|---|---|
| Access to a cell phone | 20 Participants |
| Age, Customized <= 18 | 23 Participants |
| Heard of 988 Before Baseline | 12 Participants |
| Heard of Naloxone Before Baseline | 22 Participants |
| Sex/Gender, Customized Female | 4 Participants |
| Sex/Gender, Customized Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 23 |
| other Total, other adverse events | 0 / 23 |
| serious Total, serious adverse events | 0 / 23 |
Outcome results
None listed